Skip to main content

Alpine Immune Sciences, Inc.

ALPNDelisted May 20, 2024
Industry
Pharmaceutical Preparations
SEC CIK
0001626199

Alpine Immune Sciences, Inc. was delisted on May 20, 2024; its insiders filed their last Form 4 on May 20, 2024; 180 institutions reported holding it in 13F filings for Q1 2024, worth $2.56B in total; no superinvestor held it.

Q2 2021 vs. Q1 2021

How the institutions holding Alpine Immune Sciences, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of ALPN: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders4847−1
Shares13.7M13.2M−533.4K (−3.9%)
Value$145.0M$118.5M−$26.5M (−18.3%)

New holders (15)

Institutions that held Alpine Immune Sciences, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to ALPN in Q2 2021
InstitutionSharesValue% of portfolio
State Street Corp173,119$1.56M0.00%
Bridgeway Capital Management, LLC153,611$1.38M0.02%
Alps Advisors Inc31,498$283.0K0.00%
Charles Schwab Investment Management Inc28,760$259.0K0.00%
Nuveen Asset Management, LLC18,446$166.0K0.00%
California State Teachers Retirement System16,137$145.0K0.00%
Western Wealth Management, LLC12,000$108.0K0.01%
New York State Common Retirement Fund10,300$93.0K0.00%
American International Group, Inc.6,509$59.0K0.00%
JPMorgan Chase & Co4,460$40.0K0.00%
STRS Ohio2,700$24.0K0.00%
Legal & General Group Plc1,227$11.0K0.00%
Ameritas Investment Partners, Inc.911$8.00K0.00%
Royal Bank of Canada795$7.00K0.00%
BNP Paribas Arbitrage, SA448$4.03K0.00%

Sold out (16)

Institutions that held Alpine Immune Sciences, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.